PRTC
HEALTHCAREPureTech Health Plc
$17.01+0.32 (+1.89%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PRTC Today?
No stock-specific AI insight has been generated for PRTC yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$14.50$19.92
$17.01
Fundamentals
Market Cap$406M
P/E Ratio—
EPS$-4.60
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume19K
Avg Volume (10D)—
Shares Outstanding24.3M
PRTC News
21 articles- Seaport Therapeutics stock pops 17% on Nasdaq debutQz·May 1, 2026
- PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPOProactive Investors·May 1, 2026
- PureTech Health H2 Earnings Call HighlightsMarketbeat·Apr 29, 2026
- PureTech Announces Annual Results for Year Ended December 31, 2025Yahoo Finance·Apr 29, 2026
- PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock ExchangeYahoo Finance·Apr 29, 2026
- Psychiatry Drugmaker Seaport Seeks $212.4 Million in US IPOYahoo Finance·Apr 27, 2026
- PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of DirectorsYahoo Finance·Apr 27, 2026
- PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)Yahoo Finance·Apr 22, 2026
- PureTech Health: Notice of ResultsYahoo Finance·Apr 13, 2026
- Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsightGlobeNewswire Inc.·Apr 8, 2026
- PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care MedicineYahoo Finance·Apr 2, 2026
- PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy VolunteersYahoo Finance·Apr 2, 2026
- PureTech Founded Entity Seaport Therapeutics Announces Publication in Science Translational Medicine Featuring GlyphAllo™ (SPT-300) as the First Triglyceride-Mimetic Prodrug to Achieve Therapeutically Relevant Drug Levels in HumansYahoo Finance·Mar 25, 2026
- PureTech to Present at the Leerink Partners Global Healthcare ConferenceYahoo Finance·Feb 25, 2026
- PureTech Announces Orphan Drug Designations Granted by the U.S. Food and Drug Administration and European Commission for Deupirfenidone (LYT-100) in Idiopathic Pulmonary FibrosisYahoo Finance·Feb 19, 2026
- PureTech to Present at 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 6, 2026
- PureTech Health plc (LON:PRTC) is favoured by institutional owners who hold 73% of the companyYahoo Finance·Jan 3, 2026
- PureTech Appoints Robert Lyne as Chief Executive OfficerYahoo Finance·Dec 18, 2025
- PureTech Health Completes End-of-Phase 2 Meeting With FDA for Deupirfenidone to Treat Idiopathic Pulmonary FibrosisYahoo Finance·Dec 8, 2025
- PureTech Announces Successful End-of-Phase 2 Meeting with FDA for Deupirfenidone (LYT-100) in Idiopathic Pulmonary FibrosisYahoo Finance·Dec 8, 2025
- PureTech’s Founded Entity Gallop Oncology Announces Positive Initial Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic SyndromeYahoo Finance·Dec 5, 2025
All 21 articles loaded
Price Data
Open$16.89
Previous Close$16.69
Day High$17.50
Day Low$16.83
52 Week High$19.92
52 Week Low$14.50
52-Week Range
$14.50$19.92
$17.01
Fundamentals
Market Cap$406M
P/E Ratio—
EPS$-4.60
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume19K
Avg Volume (10D)—
Shares Outstanding24.3M
About PureTech Health Plc
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops and markets drugs for inflammatory, fibrotic and immune, intractable, lymphatic and gastrointestinal, neurological and neuropsychological cancers and other diseases in the United States. The company is headquartered in Boston, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—